摘要
目的:观察复方黄连降糖散对糖尿病肾病大鼠肾脏的保护作用,对肾脏蛋白激酶C(PKC)活性以及钠离子通道的影响。方法:利用链脲佐菌素(STZ)建立大鼠的DN模型,建模成功后随机分为4组,即对照组、模型组、复方黄连降糖散组、贝那普利(洛汀新)组,在药物干预12周之后,检测大鼠背神经节中钠离子通道蛋白及mRNA水平,同时测定相对肾质量、血糖、尿蛋白排泄率(UPER)、血肌酐(SCr)、尿肌酐(UCr)、内生肌酐清除率(CCr)、肾脏PKC活性等。结果:糖尿病周围神经病变过程中,钠离子通道蛋白v1.7表达异常,与对照组相比,模型组与复方黄连降糖散组、贝那普利组钠离子通道蛋白显著上调。DN大鼠肾脏沉积明显,相对肾质量、血糖、UPER、CCr、肾脏PKC活性显著升高,贝那普利、复方黄连降糖散能够显著降低肾脏PKC活性,改善DN大鼠的蛋白尿、肾功能。结论:贝那普利、复方黄连降糖散能够保护DN大鼠肾脏,同时可以显著下调DN大鼠背根神经节中钠离子通道蛋白及mRNA的表达水平。
OBJECTIVE To observe the protection of compound berberine tablets on kidney of rats with diabetic nephropathy(DN),the effect on activity of protein kinase C(PKC)and sodium ion channel.METHODS Streptozotocin(STZ)was used to construct DN rat models,which were randomly assigned into 4 groups,namely control group,model group,compound berberine tablet group and lotensin group.After drug intervention for 12 weeks,the rat dorsal ganglion Na ion channel protein and mRNA levels were detected.Meanwhile relative kidney weight,blood glucose,urinary protein excretion rate(UAER),serum creatinine(SCR),urine creatinine(UCR),creatinine clearance rate(CCR),the activity of PKC in kidney,etc.were determined.RESULTS In the course of diabetic peripheral neuropathy,Na+channel protein V1.7 was abnormally expressed,obviously elevated in model group,compound berberine tablet group and lotensin group compared with control group.DN rats had obvious renal deposition,significantly increased relative kidney weight,blood glucose,UAER and CCR,renal PKC activity.Lotensin and compound berberine tablets significantly reduced the activity of PKC in kidney,and improved proteinuria and renal function in DN rats.CONCLUSION Lotensin and compound berberine tablets can protect the kidney of DN rats,and meanwhile can significantly reduce Na ion channel protein expression levels in DN rat dorsal root ganglion.
作者
陈国超
刘静
CHEN Guo-chao;LIU Jing(Department of Endocrinology,Wuchang Hospital,Hubei Wuhan 4300063,China;De parlment of TCM,Wuchang Hospital,Hubei Wuhan 430063,China)
出处
《中国医院药学杂志》
CAS
北大核心
2018年第18期1936-1939,共4页
Chinese Journal of Hospital Pharmacy
基金
武汉市卫计委科研基金(编号:WZ17C09)